EP3325005A4 - Identification of immunogenic mhc class ii peptides for immune-based therapy - Google Patents
Identification of immunogenic mhc class ii peptides for immune-based therapy Download PDFInfo
- Publication number
- EP3325005A4 EP3325005A4 EP16828158.2A EP16828158A EP3325005A4 EP 3325005 A4 EP3325005 A4 EP 3325005A4 EP 16828158 A EP16828158 A EP 16828158A EP 3325005 A4 EP3325005 A4 EP 3325005A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptides
- immune
- identification
- mhc class
- based therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002163 immunogen Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2015/041034 WO2016011432A2 (en) | 2014-07-17 | 2015-07-17 | Identification of immunogenic mhc class ii peptides for immune-based therapy |
PCT/US2016/021042 WO2017014810A1 (en) | 2015-07-17 | 2016-03-04 | Identification of immunogenic mhc class ii peptides for immune-based therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3325005A1 EP3325005A1 (en) | 2018-05-30 |
EP3325005A4 true EP3325005A4 (en) | 2019-03-27 |
Family
ID=57835029
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16828158.2A Withdrawn EP3325005A4 (en) | 2015-07-17 | 2016-03-04 | Identification of immunogenic mhc class ii peptides for immune-based therapy |
EP16828163.2A Withdrawn EP3324990A4 (en) | 2015-07-17 | 2016-04-07 | Identification of immunogenic mhc class ii peptides for immune-based therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16828163.2A Withdrawn EP3324990A4 (en) | 2015-07-17 | 2016-04-07 | Identification of immunogenic mhc class ii peptides for immune-based therapy |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP3325005A4 (en) |
JP (3) | JP2018527286A (en) |
CN (1) | CN107206045A (en) |
CA (2) | CA2992925A1 (en) |
WO (2) | WO2017014810A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017014810A1 (en) * | 2015-07-17 | 2017-01-26 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008214A1 (en) * | 1989-12-01 | 1991-06-13 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL145926A0 (en) * | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
CA2480099C (en) * | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
WO2007115571A2 (en) * | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
JP5566687B2 (en) * | 2006-06-15 | 2014-08-06 | ノバルティス アーゲー | Multi-dose vaccination regimen without adjuvant |
CA2753119A1 (en) * | 2009-02-24 | 2010-09-02 | F. Hoffmann-La Roche Ag | Use of s-erbb-3 as a marker for cancer |
JP2010200693A (en) * | 2009-03-04 | 2010-09-16 | Chiyoda Kako Kensetsu Kk | Culture device for producing dendritic cell vaccine and method for producing the dendritic cell |
US8765383B2 (en) * | 2009-04-07 | 2014-07-01 | Genomic Health, Inc. | Methods of predicting cancer risk using gene expression in premalignant tissue |
WO2011014871A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
BR112012023285A2 (en) * | 2010-03-15 | 2018-12-11 | Univ Pennsylvania | methods for generating antigen-loaded dendritic cells and for eliciting an immune response in a mammal; and, preservative composition. |
JP2014516960A (en) * | 2011-05-19 | 2014-07-17 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | Anti-human HER3 antibody and use thereof |
ES2758433T3 (en) * | 2011-12-05 | 2020-05-05 | Novartis Ag | Antibodies to epidermal growth factor receptor 3 (HER3) |
AU2014324478A1 (en) * | 2013-09-30 | 2016-05-05 | Amgen, Inc. | Nucleic acid biomarker and use thereof |
WO2016011432A2 (en) * | 2014-07-17 | 2016-01-21 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
WO2017014810A1 (en) * | 2015-07-17 | 2017-01-26 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
-
2016
- 2016-03-04 WO PCT/US2016/021042 patent/WO2017014810A1/en active Application Filing
- 2016-03-04 CA CA2992925A patent/CA2992925A1/en not_active Abandoned
- 2016-03-04 EP EP16828158.2A patent/EP3325005A4/en not_active Withdrawn
- 2016-03-04 JP JP2017502790A patent/JP2018527286A/en active Pending
- 2016-04-07 CN CN201680002764.1A patent/CN107206045A/en active Pending
- 2016-04-07 WO PCT/US2016/026542 patent/WO2017014816A1/en active Application Filing
- 2016-04-07 JP JP2017502788A patent/JP2018521953A/en active Pending
- 2016-04-07 CA CA2992937A patent/CA2992937A1/en not_active Abandoned
- 2016-04-07 EP EP16828163.2A patent/EP3324990A4/en not_active Withdrawn
-
2020
- 2020-10-14 JP JP2020173500A patent/JP2021043204A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008214A1 (en) * | 1989-12-01 | 1991-06-13 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
Non-Patent Citations (2)
Title |
---|
DUNFA PENG ET AL: "Alterations in Barrett's-related adenocarcinomas: A proteomic approach", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 6, 15 March 2008 (2008-03-15), pages 1303 - 1310, XP055178816, ISSN: 0020-7136, DOI: 10.1002/ijc.23258 * |
See also references of WO2017014810A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP3324990A1 (en) | 2018-05-30 |
EP3324990A4 (en) | 2019-04-03 |
JP2018527286A (en) | 2018-09-20 |
WO2017014816A1 (en) | 2017-01-26 |
JP2021043204A (en) | 2021-03-18 |
CA2992925A1 (en) | 2017-01-26 |
JP2018521953A (en) | 2018-08-09 |
CN107206045A (en) | 2017-09-26 |
WO2017014810A1 (en) | 2017-01-26 |
EP3325005A1 (en) | 2018-05-30 |
CA2992937A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3291842A4 (en) | Variant survivin vaccine for treatment of cancer | |
PL3207053T3 (en) | Novel immunogenic peptides | |
ZA201806860B (en) | Novel immunogenic cd1d binding peptides | |
EP3220953A4 (en) | COMPOSITIONS AND METHODS OF USING THERAPEUTIC p53 PEPTIDES AND ANALOGUES | |
ZA201808246B (en) | Improvement of hpv l2 peptide immunogenicity | |
EP3523274A4 (en) | Formulations for administration of eflornithine | |
EP3199627A4 (en) | Tumor antigen peptides | |
EP3152236A4 (en) | Method for decreasing immunogenicity of protein and peptide | |
IL265805A (en) | Immunogenic arginase peptides | |
EP3315599A4 (en) | Oral tumor vaccine | |
HK1250662A1 (en) | Immunogenic fusion proteins for the treatment of cancer | |
EP3178491A4 (en) | Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition | |
EP3283095A4 (en) | Therapeutic peptides for cerebrovascular diseases | |
EP3107450A4 (en) | Cosmetic base matching system | |
EP3231867A4 (en) | Tumor antigen peptide | |
EP3223016A4 (en) | Peptides for targeting gastric cancer, and medical use thereof | |
EP3331544A4 (en) | Identification of class i mhc associated glycopertides as targets for cancer immunotherapy | |
EP3313427A4 (en) | Therapeutic peptides and methods of use thereof | |
EP3169354A4 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
EP3336186A4 (en) | Depdc1-derived peptide and vaccine containing same | |
AU2015300256B2 (en) | KOC1-Derived peptide and vaccine including same | |
EP3189852A4 (en) | Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity | |
EP3162378A4 (en) | Influenza vaccine nasal vaccination system | |
EP3324990A4 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
EP3222289A4 (en) | Dna-peptide combination vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20170217 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190221 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20190215BHEP Ipc: C07K 14/71 20060101ALI20190215BHEP Ipc: A61K 39/00 20060101ALI20190215BHEP Ipc: A61P 35/00 20060101ALI20190215BHEP Ipc: C12N 5/0783 20100101ALI20190215BHEP Ipc: C12N 5/0784 20100101ALI20190215BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190924 |